期刊文献+

蜂蜡素固体分散体对高脂血症大鼠脂代谢的影响 被引量:1

Effect of Fenglasu solid dispersion on lipid metabolism in hyperlipoidemia rats
原文传递
导出
摘要 目的:观察蜂蜡素(Fenglasu,FLS)及蜂蜡素固体分散体(Fenglasu solid dispersion,FLS-SD)对高脂血症大鼠脂代谢的影响。方法:高脂饲料喂养制备高脂血症大鼠模型,分别给予高,中,低剂量FLS及FLS-SD(50,100,200 mg·kg-1·d-1),测定大鼠血清中胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白(LDL-C)、高密度脂蛋白(HDL-C)、载脂蛋白A1(apoA1)、载脂蛋白B100(apoB100)含量,计算LDL-C/HDL-C和apoA1/apoB100的比值。结果:FLS及FLS-SD均呈剂量和时间依赖性显著降低高血脂大鼠血清TC,TG,LDL-C,apoB100和LDL-C/HDL-C比值,显著升高HDL-C、apoA1和apoA1/apoB100比值,且FLS-SD作用强于FLS。结论:FLS-SD可有效调节高脂血症大鼠的脂代谢紊乱。 Objective: To observe the effects of Fenglasu (FLS) and Fenglasu solid dispersion (FLS-SD) on lipid metabolism in byperlipoidemia rats. Methods: Hyperlipoidemia rat was induced by feeding with high lipid diets, and FLS and FLS-SD (50, 100, 200 mg·kg^-l·d^-1) were preventively administered. TC, TG, LDL-C, HDL-C, apoA1, and apoB100 were determined, LDL-C/HDL-C and apoA1/apoBlo0 were calculated. Results: FLS and FLS-SD decreased the levels of TC, TG, LDL-C, apoB1oo , and LDL-C/HDL-C ; increased the levels of HDL- C, apoA1 , apoA1/apoBl00 in dose- and time-dependent manners. The effect of FLS-SD was more potent than that of FLS. Conclusion: FLS-SD can effectively adjust lipid metabolic disorder in hyperlipoidemia rats.
出处 《中国新药杂志》 CAS CSCD 北大核心 2011年第11期1034-1037,共4页 Chinese Journal of New Drugs
关键词 蜂蜡素 固体分散体 高脂血症 脂代谢 Fenglasu solid dispersion hyperlipoidemia lipid metabolism
  • 相关文献

参考文献7

  • 1廖芳,张小娜.新型降胆固醇药物蜂蜡素胶囊[J].中国药师,2005,8(12):1039-1040. 被引量:9
  • 2杨丽,张小娜.蜂蜡素对HepG2细胞胆固醇生物合成的影响[J].中国药师,2008,11(10):1154-1157. 被引量:1
  • 3廖芳,钟琳玲,张小娜.蜂蜡素对HepG_2细胞HMG-CoA还原酶mRNA表达及蛋白质水平的影响[J].中国新药杂志,2009,18(4):345-348. 被引量:1
  • 4SIVAKUMAR SWAMY G, RAMANARAYAN K, INAMDAR LS, et al. Triacontanol and jasmonie acid differentially modulate the lipid organization as evidenced by the fluorescent probe behavior and 31P nuclear magnetic resonance shifts in model membranes [J]. J Membr Biol, 2009, 228(3):165 -177.
  • 5SINGH DK, LI L, PORTER TD. Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase [ J ]. J Pharmacol Exp Ther, 2006,318 ( 3 ) : 1020 - 1026.
  • 6DAVIDSON MH. Apolipoprotein measurements: is more wide- spread use clinically indicated? [J ]. Clin Cardiol, 2009, 32 (9) :482 -486.
  • 7BOSSOLA M, GIUNGI S, PANOCCHIA N, et al. Body mass in- dex and cardiovascular risk factors and biomarkers in hemodialysis patients[J]. J Nephrol, 2008, 21 (2) :197 -204.

二级参考文献36

  • 1廖芳,张小娜.新型降胆固醇药物蜂蜡素胶囊[J].中国药师,2005,8(12):1039-1040. 被引量:9
  • 2王家政 范明.蛋白质技术手册[M].北京:科学技术出版社,2000.51-54.
  • 3TEUPSER D, BRUEGEL M, STEIN O, etal. HMG-CoAreductase inhibitors reduce adhesion of human monocytes to endothelial cells[J]. Biochem Biophys Res Commun, 2001, 289(4) :838 - 844.
  • 4刘斌,王为.细胞培养[M].西安:世界图书出版西安公司,2005:235-257
  • 5Choice of lipid-regulating drugs[ J ]. Med Lett Drugs Ther, 2001, 43(1105): 43-48.
  • 6KNOPP RH. Drug treatment of lipid disorders[ J]. N Engl J Med, 1999, 341(7) :498 -511.
  • 7PAOLETTI R, FAHMY M, MAHLA G, et al. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterotaemic patients : a randomized, double-blind study [ J ]. J Cardiovasc Risk, 2001,8 ( 6 ) : 383 - 390.
  • 8DAVIDSON MH. Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia [J]. Expert Opin lnvestig Drugs, 2002, 11(3) :125 -141.
  • 9DIMITROULAKOS J, NOHYNEK D, BACKWAY KL, et al. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach [J]. Blood, 1999, 93(4) :1308-1318.
  • 10DUCOBU J. Hypercholesterolemia: to treat or not to treat? That is the question[J]. Rev Med Brux, 1994, 15(3) :124-131.

共引文献8

同被引文献15

引证文献1

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部